Literature DB >> 7702232

Amiodarone: reevaluation of an old drug.

P J Podrid1.   

Abstract

PURPOSE: To review the pharmacology, electrophysiology, and toxicity of amiodarone and to discuss the clinical results produced when amiodarone is used as therapy for patients with atrial fibrillation, patients with nonsustained ventricular tachycardia and cardiomyopathy, patients who have recently had myocardial infarctions, and patients who have survived out-of-hospital cardiac arrest caused by ventricular tachycardia or ventricular fibrillation. DATA SOURCES: Animal and clinical studies involving the pharmacology and electrophysiology of amiodarone and clinical trials in which amiodarone was used as therapy for the arrhythmias noted above were reviewed. STUDY SELECTION: Relevant studies that reported on the efficacy and toxicity of amiodarone and on long-term therapy using amiodarone were reviewed, and their data were summarized. Reports of ongoing trials using amiodarone were also reviewed and summarized.
RESULTS: Amiodarone is useful for the treatment of many rhythm disturbances. Although side effects from this agent are common, serious toxicity necessitating discontinuation of therapy is infrequent. Unlike other antiarrhythmic agents, amiodarone has not been shown to increase mortality in any population studied.
CONCLUSION: Amiodarone, a unique antiarrhythmic agent with many pharmacologic actions, is effective in the treatment of a wide range of rhythm abnormalities. Several large, randomized trials will provide further information about the clinical usefulness of this agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702232     DOI: 10.7326/0003-4819-122-9-199505010-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  23 in total

Review 1.  Treatment of atrial flutter.

Authors:  A L Waldo
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

2.  Na+-K+ pump inhibition caused by chronic amiodarone in guinea pig myocardium.

Authors:  T Maruyama; N Ueda; Y Kaji; S Kanaya; T Fujino; Y Niho
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

3.  Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects.

Authors:  Tsuyoshi Shiga; Takanori Tanaka; Shin Irie; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2010-10-30       Impact factor: 2.037

4.  Sudden hypothyroidism and amiodarone-lithium combination: an interaction.

Authors:  S Ahmad
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

Review 5.  Can antiarrhythmic agents be selected based on mechanism of action?

Authors:  W Lau; D Newman; P Dorian
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

6.  Unusual amiodarone toxicity in a child.

Authors:  Bahram Kakavand; Thomas G Di Sessa
Journal:  J Pediatr Pharmacol Ther       Date:  2008-04

7.  Antiarrhythmic drug therapy.

Authors:  Brian R Triola; Peter R Kowey
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-09

Review 8.  Drug-induced steatohepatitis.

Authors:  Vaishali Patel; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

9.  The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.

Authors:  Jakob Gierten; Eckhard Ficker; Ramona Bloehs; Patrick A Schweizer; Edgar Zitron; Eberhard Scholz; Christoph Karle; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-24       Impact factor: 3.000

Review 10.  Cost effectiveness of therapies for atrial fibrillation. A review.

Authors:  M P Teng; L E Catherwood; D P Melby
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.